<?xml version="1.0" encoding="UTF-8"?>
<p>An additional advantage of LAIVs is their consumer‐friendly needle‐free intranasal application which represents a minimal invasive delivery method, and it is expected with higher production capacities and a more widely distribution. For these reasons, its expanded use could increase the influenza vaccination coverage globally. Furthermore, it may represent a favorable approach for mass immunizations, especially in younger children since its application is not associated with pain.
 <xref rid="irv12664-bib-0087" ref-type="ref">87</xref>
</p>
